Abstract
The bone marrow immunosuppressive microenvironment of AML patients sustains and modulates proliferation, survival and drug resistance of AML through deregulation of both innate and adaptive immune response. We aimed to investigate the level of Tregs, expression of Tim-3 on peripheral blood T cells, expression of CD200 in myeloid blasts in newly diagnosed AML patients with normal cytogenetics (AML-NC) and their prognostic impact. This study included 40 patients with de novo AML-NC and 20 healthy controls. Flow-cytometry was used for detection of CD4+CD25+high FoxP3+ regulatory T cells, Tim-3 expression on peripheral blood T cells and CD200 expression on myeloid blasts. The percentages of CD4+CD25+high and CD4+CD25+high Foxp3+ Tregs were significantly increased in AML patients than controls. The levels of Tregs, Tim-3/CD4+, Tim-3/CD8+, CD200 and MFI of CD200 were significantly lower in responding patients than in those with persistent leukemia. Only high CD200 expression (> 50%) showed statistically significant worse OS with P< 0.04. The increased levels of Tregs, Tim-3 expression on peripheral blood T cells and CD200 expression in myeloid blast in AML patients could play a role in the development of AML. Analysis of these marker...Continue Reading
References
Jun 20, 2002·Trends in Immunology·A Neil BarclayMarion H Brown
Nov 16, 2005·Nature Immunology·Chen ZhuVijay K Kuchroo
Jan 26, 2007·Leukemia·A TonksR L Darley
Aug 5, 2008·Cancer Research·Cynthia LeheSaid Dermime
Oct 8, 2008·Leukemia Research·Christian P PallaschClemens-Martin Wendtner
May 7, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Miroslaw J SzczepanskiMichael Boyiadzis
Jun 6, 2009·Journal of Hematology & Oncology·Tara K GregoryWilliam Tse
Nov 3, 2009·Blood·Hartmut DöhnerUNKNOWN European LeukemiaNet
Jun 19, 2010·Blood·Jacob M Rowe, Martin S Tallman
Oct 20, 2010·Expert Opinion on Biological Therapy·Eyad ElkordDavid E Gilham
Dec 25, 2010·European Journal of Immunology·Kazuki SakaiTaira Maekawa
Mar 10, 2011·Blood·Qing ZhouBruce R Blazar
Sep 9, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Evan J Lipson, Charles G Drake
Oct 20, 2011·Cancer Research·Shin Foong NgiowMark J Smyth
Dec 20, 2011·American Journal of Clinical Pathology·Daisy AlapatRobert B Lorsbach
Mar 21, 2012·Leukemia·S J ColesA Tonks
Nov 28, 2012·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Ali MemarianMahmood Jeddi-Tehrani
Apr 2, 2013·Journal of Theoretical Biology·Kang-Ling LiaoAvner Friedman
May 15, 2013·Journal of Leukocyte Biology·Margaret K Callahan, Jedd D Wolchok
Dec 20, 2013·Journal for Immunotherapy of Cancer·Ryan M Teague, Justin Kline
May 6, 2014·Cancer Immunology Research·Ana C Anderson
Jun 21, 2014·Blood·Cliona M Rooney
Sep 18, 2014·Expert Review of Hematology·Alessandro IsidoriAntonio Curti
Sep 5, 2015·Oncotarget·Daniela DamianiRenato Fanin
Mar 10, 2016·Journal of Clinical Medicine·Jennifer N Saultz, Ramiro Garzon
Apr 14, 2017·Leukemia Research·Mario TiribelliDaniela Damiani
Citations
Jun 6, 2019·Nanomedicine·Noura H Abd EllahHelal F Hetta
Mar 15, 2020·Cancer Immunology, Immunotherapy : CII·Asmaa M ZahranOmnia El-Badawy
Mar 5, 2020·Oncogene·Zhuoyan LiP Brent Ferrell
Feb 23, 2020·Leukemia & Lymphoma·Asmaa M ZahranHelal F Hetta
Mar 19, 2020·Frontiers in Oncology·Rebecca EpperlyM Paulina Velasquez
Jun 27, 2019·Expert Opinion on Therapeutic Patents·Irma Herrera-CamachoGerardo Landeta
Feb 23, 2020·Biomarker Research·Jiaxiong TanYangqiu Li
Jan 10, 2021·Purinergic Signalling·Wen-Jun Zhang
Dec 29, 2020·Experimental and Molecular Pathology·Eman Z KandeelNevine F Shafik
Feb 11, 2021·International Journal of Molecular Sciences·Katarzyna Kotwica-MojzychMariusz Mojzych
Feb 1, 2020·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Wen-Jun ZhangHong-Liang Luo
Oct 19, 2021·Frontiers in Oncology·Mahnaz RezaeiMazdak Ganjalikhani-Hakemi